# Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

> **NCT00119314** · PHASE2 · WITHDRAWN · sponsor: **University of Medicine and Dentistry of New Jersey**

## Conditions studied

- Carcinoma of Unknown Primary

## Interventions

- **DRUG:** capecitabine
- **DRUG:** docetaxel
- **DRUG:** gemcitabine hydrochloride
- **PROCEDURE:** positron emission tomography

## Key facts

- **NCT ID:** NCT00119314
- **Lead sponsor:** University of Medicine and Dentistry of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-07
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2015-05-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00119314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00119314, "Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00119314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*